#USA #Fremont #Alamar Biosciences #NULISAseq #Inflammation Panel

Alamar Biosciences Unveils the NULISAseq Inflammation Panel AQ

Alamar Biosciences, a leader in precision proteomics, has recently introduced the NULISAseq™ Inflammation Panel AQ, a groundbreaking tool aimed at refining the profiling of immune responses in both clinical and longitudinal studies. This innovative panel represents a remarkable progression in the detection and analysis of protein biomarkers essential for understanding various diseases.

Unparalleled Sensitivity and Precision

The NULISAseq Inflammation Panel AQ distinguishes itself by offering unrivaled sensitivity, boasting over 99% quantifiability in normal samples. This allows researchers to detect minute changes in immune responses which may occur either from the onset of disease or following therapeutic interventions. As a result, clinicians and researchers can monitor immune responses more accurately and effectively than ever before.

With the ability to quantify over 150 key protein biomarkers from a single sample, the panel ensures comprehensive data collection. It reconciles the challenges often faced in biomarker discovery, where subtle variations can hold significant clinical implications.

Exceptional Dynamic Range

The NULISAseq Inflammation Panel AQ features an extensive dynamic range of over 9 logs, enabling the simultaneous quantification of both high- and low-abundance proteins. This robust capability ensures collection of a well-rounded dataset, essential for discovering new disease signatures or understanding therapeutic efficacy in clinical applications.

Specifically, this means that researchers can monitor a wide array of proteins in one go, making experiments more efficient and cost-effective. This broad dynamic range is vital in the realm of oncology, autoimmune diseases, and infectious diseases where the relative levels of various proteins can fluctuate dramatically.

High Reproducibility for Reliable Results

One of the key attributes of the NULISAseq Inflammation Panel AQ is its high reproducibility, achieving a mean coefficient of variation (CV) of less than 10%. Such consistency is paramount in large-scale clinical studies where the integrity and reliability of data can directly influence outcomes and conclusions drawn from research. Researchers increasingly rely on reproducibility for validating their findings and drawing accurate inferences.

Transformative Technology Behind NULISAseq

The NULISAseq Inflammation Panel AQ is built on Alamar Biosciences' proprietary NULISA™ technology. This advanced platform amalgamates a patented sequential immunocomplex capture and release framework with next-generation sequencing, providing a multiplexed, high-sensitivity protein analysis. In doing so, it confronts the critical challenge of sample limitations commonly encountered in research settings. The panel is adept even with minimal sample sizes, requiring just 10μL of sample for operation.

This innovative technology is ideally suited to applications spanning various fields, including oncology, autoimmune conditions, and infectious diseases, where sample limitations often thwart research progress.

A Leap Forward in Precision Research

Yuling Luo, Chairman and CEO of Alamar Biosciences, expressed enthusiasm about the potential impact of the NULISAseq Inflammation Panel AQ on immune system research. He noted, “The NULISAseq Inflammation Panel AQ is the largest panel for absolute quantification available and represents a major leap forward in precision proteomics. Its unprecedented sensitivity and dynamic range provide researchers with the tools to push the boundaries of immune system research, ultimately advancing our understanding of health and disease.”

In summary, the advent of the NULISAseq Inflammation Panel AQ by Alamar Biosciences sets a new standard in the profiling of immune responses, providing researchers with powerful tools to unlock insights into disease progression and therapeutic responses. The potential applications of this technology in precision medicine are vast, spotlighting its significance in shaping the future of clinical research.

For further details about the NULISAseq Inflammation Panel AQ, you can visit alamarbio.com/inflamAQ.